HIV News and Research

RSS

If started early, HIV treatment reduces death rates toward background levels in African countries

Mortality rates of people starting HIV treatment in four African countries approach those of the general population over time, provided that treatment is started before the immune system has been severely damaged, according to research published this week in the open-access journal PLoS Medicine.

30 Apr 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Test for best potential HIV/AIDS vaccine in the pipeline

Scientists in Britain are well on the way to developing a test for the best potential HIV/AIDS vaccine.

27 Apr 2009

Australian researchers win bumper grant from Bill Gates for HIV research

Australian researchers have won themselves a bumper grant from the Bill & Melinda Gates Foundation to examine the best way of using drugs to treat HIV.

27 Apr 2009

Circumcision reduces risk of contracting HIV without reducing sexual pleasure

Two studies presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA) show that adult circumcision reduces the risk of contracting the human immunodeficiency virus (HIV) and the risk of coital injury without reducing pleasure or causing sexual dysfunction.

26 Apr 2009

Natural plant cannabinoids reduce multi-drug resistant infections

Cannabis Science, Inc., Dr. Robert Melamede, PhD., Director and Chief Science Officer, reported to the Board on the current state of research into the use of natural plant cannabinoids to reduce the spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus (MRSA), and the prospects for development of topical whole-cannabis treatments.

23 Apr 2009

Palliative care skills training needed for health-care staff in sub-Saharan Africa

A new study, led by Lucy Selman and colleagues from King's College London, has found that patients with incurable, progressive diseases and their family carers in sub-Saharan Africa often do not receive enough information about the patient's disease and its management, which impacts negatively on their ability to cope with illness.

22 Apr 2009

Why an effective vaccine for HIV has proven so elusive

Some 25 years after the AIDS epidemic spawned a worldwide search for an effective vaccine against the human immunodeficiency virus (HIV), progress in the field seems to have effectively become stalled.

22 Apr 2009

Rifampin kinetics poor in children

Rifampin (RMP), a first-line antituberculosis drug, reaches serum concentrations well below suggested lower limits when a standard dose of 8-12mg/kg body weight is given to children.

22 Apr 2009

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

NanoBio has announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

20 Apr 2009

Humanized mouse infected with HIV vaginally and rectally allows testing

The "humanized mouse" developed by Dr. J. Victor Garcia-Martinez has allowed the University of Texas Southwestern physician-scientist to conduct HIV/AIDS studies that would have been impossible without such a small animal model of HIV infection.

20 Apr 2009

GlaxoSmithKline and Pfizer team up to form HIV company

Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

16 Apr 2009

NIH grants will strengthen fight against HIV/AIDS-tuberculosis

The Fogarty International Center of the National Institutes of Health today announced it will award $11.75 million over five years in grants to institutions to strengthen the fight against HIV/AIDS and tuberculosis in Haiti, Uganda and China and establish a new program in Tanzania.

16 Apr 2009

New updated clinical guidelines for HIV-associated opportunistic infections

The first complete update in five years of the U.S. guidelines for preventing and treating HIV-associated opportunistic infections has been released by the National Institutes of Health and the Centers for Disease Control and Prevention in cooperation with the HIV Medicine Association of the Infectious Diseases Society of America (IDSA).

16 Apr 2009

Tijuana injection drug users on collision course for HIV and tuberculosis

A study by researchers from the University of California, San Diego School of Medicine, in collaboration with Mexican researchers and health officials, shows that as many as 67 percent of injection drug users in Tijuana test positive for tuberculosis (TB) infection.

15 Apr 2009

Discovery of a new target for novel HIV treatment strategy

The AIDS-causing HIV specifically counteracts the mechanisms of human cells that protect these against viral infections - a special viral protein marks protective cellular proteins for their rapid destruction and thus diminishes the cell's supply.

15 Apr 2009

Early HIV treatment decreases the risk of death

Begin treatment as early as possible: this general common sense rule seems to apply to most diseases except HIV-AIDS, which is only treated once a certain number of immune cells called "CD4+" cells have disappeared.

14 Apr 2009

New AIDS research training grants awarded for projects in 15 countries

The Fogarty International Center of the National Institutes of Health has awarded seven grants totaling almost $2.7 million to train HIV/AIDS researchers in 15 low- and middle-income countries.

14 Apr 2009

HIV infection rates are lower in circumcised heterosexual men

Three recent African trials support male circumcision for reducing the risk of contracting HIV in heterosexual men.

14 Apr 2009

Mutations that help HIV hide undermine the virus's ability to replicate

When HIV infects a cell, a complex of human immune proteins called HLA (short for human leukocyte antigen) alert killer T cells by displaying bits of the virus on the surface of the cell. The T cells recognize these HIV fragments and mobilize an attack.

13 Apr 2009